Open · 685 days left D National Institutes of Health

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
Jan 07, 2028
Posted Oct 28, 2024 (480 days ago)
Closes Jan 7, 2028 (in 685 days)

Grant Details

Opportunity Number
PAR-25-024
CFDA / ALN
93.853, 93.866
Opportunity Category
Discretionary (D)
Funding Category
Health (HL)
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)

Eligibility

State governments (00) County governments (01) City or township governments (02) Special district governments (04) Independent school districts (05) Public and State controlled institutions of higher education (06) Native American tribal governments (Federally recognized) (07) Public housing authorities / Indian housing authorities (08) Native American tribal organizations (11) Nonprofits having a 501(c)(3) status with the IRS (12) Nonprofits without 501(c)(3) status (13) Private institutions of higher education (20) For-profit organizations other than small businesses (22) Small businesses (23) Others (25)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Description

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
Apply on Grants.gov Apply Now

Related Grants

Cooperative Agreement for affiliated Partner with the North Atlantic Coast Cooperative Ecosystem Studies Unit

Geological Survey
$498,392

New World Screwworm Grand Challenge

Animal and Plant Health Inspection Service
$5,000,000

FY 2026 National Infrastructure Investments

69A345 Office of the Under Secretary for Policy
$25,000,000

OVC FY25 Preventing Trafficking of Girls

Office for Victims of Crime
$497,000

OVC FY25 Specialized Human Trafficking Assistance: Supporting Survivor Engagement in Anti-Trafficking Programming

Office for Victims of Crime
$1,200,000

OVC FY25 Integrated Services for Minor Victims of Human Trafficking

Office for Victims of Crime
$950,000